HTLV-1 proviral load in infective dermatitis associated with HTLV-1 does not increase after the development of HTLV-1-associated myelopathy/tropical spastic paraparesis and does not decrease after IDH remission

被引:8
作者
Batista, Everton S. [1 ]
Oliveira, Pedro D. [2 ]
Primo, Janeusa [3 ]
Varandas, Cinthya Maria Neves [3 ]
Nunes, Ana Paula [4 ]
Bittencourt, Achilea L. [4 ]
Farre, Lourdes [1 ,5 ]
机构
[1] Fiocruz MS, Oswaldo Cruz Fdn, CPQGM, Lab Expt Pathol,Goncalo Moniz Res Ctr, Salvador, BA, Brazil
[2] Univ Fed Bahia, Prof Edgard Santos Teaching Hosp, Dept Internal Med, Salvador, BA, Brazil
[3] Santo Antonio Hosp Sister Dulces Social Work, Neuropediat Dept, Salvador, BA, Brazil
[4] Univ Fed Bahia, Prof Edgard Santos Teaching Hosp, Dept Pathol, Salvador, BA, Brazil
[5] IDIBELL, Catalan Inst Oncol, ProCURE Program, Barcelona, Spain
来源
PLOS NEGLECTED TROPICAL DISEASES | 2019年 / 13卷 / 12期
关键词
T-CELL LEUKEMIA/LYMPHOMA; I-ASSOCIATED MYELOPATHY; HAM/TSP; MARKER; FEATURES; ALLELES; BAHIA;
D O I
10.1371/journal.pntd.0007705
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Infective dermatitis associated with HTLV-1 (IDH) is a recurrent eczema which affects children vertically infected with HTLV-1. In Bahia, Brazil, we recently reported that 47% of IDH patients also develop juvenile HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive disabling disorder which is typically reported in adult HTLV-1 carriers. IDH may also predispose to adult T-cell leukemia/lymphoma, a neoplasm associated with HTLV-1. The factors relating to the development of HTLV-1-associated juvenile diseases have not yet been defined. HTLV-1 proviral load (PVL) is one of the main parameters related to the development of HTLV-1 associated diseases in adults. In the current study, we investigated the role of PVL in IDH and juvenile HAM/TSP. Methodology/Principal findings This is a cohort study that included fifty-nine HTLV-1 infected children and adolescents, comprising 16 asymptomatic carriers, 18 IDH patients, 20 patients with IDH and HAM/TSP (IDH/HAM/TSP) and five with HAM/TSP. These patients were followed-up for up to 14 years (median of 8 years). We found that PVL in IDH and IDH/HAM/TSP patients were similarly higher than PVL in juvenile asymptomatic carriers (p< 0.0001). In those IDH patients who developed HAM/TSP during follow-up, PVL levels did not vary significantly. HAM/TSP development did not occur in those IDH patients who presented high levels of PVL. IDH remission was associated with an increase of PVL. Inter-individual differences in PVL were observed within all groups. However, intra-individual PVL did not fluctuate significantly during follow-up. Conclusions/Significance High PVL in IDH patients was not necessary indicative of progression to HAM/TSP. PVL did not decrease after IDH remission. The maintenance of high PVL after remission could favor early development of ATL. Therefore, IDH patients would have to be followed-up even after remission of IDH and for a long period of time.
引用
收藏
页数:11
相关论文
共 19 条
[1]   Adult T-Cell Leukemia/Lymphoma in Bahia, Brazil [J].
Bittencourt, Achilea L. ;
Vieira, Maria da Gracas ;
Brites, Carlos R. ;
Farre, Lourdes ;
Barbosa, Helenemarie S. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (05) :875-882
[2]   Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: Clinical, histological and immunohistochemical features of 52 cases [J].
Bittencourt, Achilea L. ;
Barbosa, Helenemarie S. ;
Vieira, Maria Das Gracas ;
Farre, Lourdes .
ACTA ONCOLOGICA, 2009, 48 (04) :598-604
[3]   Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM) [J].
De Castro-Costa, Carlos M. ;
Araujo, Abelardo Q. C. ;
Barreto, Marcio M. ;
Takayanagui, Osvaldo M. ;
Sohler, Marzia P. ;
Da Silva, Eduardo L. M. ;
De Paula, Sonia M. B. ;
Ishak, Ricardo ;
Ribas, Joao G. R. ;
Rovirosa, Luis C. ;
Carton, Herwig ;
Gotuzzo, Eduardo ;
Hall, William W. ;
Montano, Silvia ;
Murphy, Edward L. ;
Oger, Joel ;
Remondegui, Carlos ;
Taylor, Graham P. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (10) :931-935
[4]  
Gillet NA, 2013, PLOS PATHOG, V9, DOI [10.1371/journal.ppat.1003263, 10.1371/journal.ppat.1003687]
[5]   Interferon-alpha is effective in HTLV-I-associated myelopathy: A multicenter, randomized, double-blind, controlled trial [J].
Izumo, S ;
Goto, I ;
Itoyama, Y ;
Okajima, T ;
Watanabe, S ;
Kuroda, Y ;
Araki, S ;
Mori, M ;
Nagataki, S ;
Matsukura, S ;
Akamine, T ;
Nakagawa, M ;
Yamamoto, I ;
Osame, M .
NEUROLOGY, 1996, 46 (04) :1016-1021
[6]   HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy [J].
Jeffery, KJM ;
Usuku, K ;
Hall, SE ;
Matsumoto, W ;
Taylor, GP ;
Procter, J ;
Bunce, M ;
Ogg, GS ;
Welsh, KI ;
Weber, JN ;
Lloyd, AL ;
Nowak, MA ;
Nagai, M ;
Kodama, D ;
Izumo, S ;
Osame, M ;
Bangham, CRM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3848-3853
[7]   The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type T infection [J].
Jeffery, KJM ;
Siddiqui, AA ;
Bunce, M ;
Lloyd, AL ;
Vine, AM ;
Witkover, AD ;
Izumo, S ;
Usuku, K ;
Welsh, KI ;
Osame, M ;
Bangham, CRM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :7278-7284
[8]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[9]   Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease? [J].
Martins, Marina Lobato ;
Guimaraes, Jacqueline Cronemberger ;
Ribas, Joao Gabriel ;
Romanelli, Luiz Claudio Ferreira ;
Freitas Carneiro-Proietti, Anna Barbara de .
JOURNAL OF NEUROVIROLOGY, 2017, 23 (01) :125-133
[10]   Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis [J].
Nascimento, M. C. F. ;
Primo, J. ;
Bittencourt, A. ;
Siqueira, I. ;
Oliveira, M. de Fatima ;
Meyer, R. ;
Schriefer, A. ;
Santos, S. B. ;
Carvalho, E. M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (03) :455-462